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Background: Recently, laparoscopic resection for relatively small sized gastric gastrointestinal stromal tumors
(GISTs) has been widely accepted as minimally invasive surgery. However, no report on the long-term safety and
efficacy of this surgery for large sized gastric GISTs has been published to date.
Methods: Between July 1998 and January 2011, 104 consecutive patients who underwent resection for gastric
GISTs were enrolled in this retrospective study. We assessed the clinicopathological characteristics, postoperative
outcomes, patient survival, and tumor recurrence.
Results: Of the 104 patients with gastric GISTs who were included in the study, there were 47 males and 57
females whose mean age was 59.8 years. Sixty-four patients (61.5%) had symptoms associated with tumor. Ten
patients included in the group 1, 49 in the group 2, 15 in the group 3a, 9 in the group 5, 14 in the group 6a, and 7 in
the group 6b. There was one minor complication and no mortalities. Recurrence was noted in 5 patients, with a
median follow-up period of 49.3 months (range, 8.4 to 164.4). The 5-year overall and disease free survival rates of
104 patients were 98.6% and 94.8%, respectively. When comparing large tumor (5–10 cm) between laparoscopic
and open surgery, there were statistically differences in age, tumor size, tumor location, and length of
hospitalization. There were no statistical differences in the 5-year survival rate between laparoscopic and open
surgery for large tumor (5-10cm).
Conclusion: Laparoscopic surgery is feasible and effective as an oncologic treatment of gastric GISTs. Moreover,
laparoscopic surgery can be an acceptable alternative to open methods for gastric GISTs of size bigger than 5 cm.
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Gastrointestinal stromal tumors (GISTs) represent a rare
but distinct histopathological group of intestinal neo-
plasms of mesenchymal origin. Their incidence is only
0.2% of all gastrointestinal malignancies [1]. Despite the
development of a new chemotherapeutic agent, imatinib
mesylate, surgery remains the only curative treatment for
non-metastatic gastric GIST [2]. Resection with a negative
margin should be performed. Lymphadenectomy is not
necessary, because gastric GISTs rarely metastasize to the
lymph node [3]. Wedge resection has been practiced in* Correspondence: mckim@donga.ac.kr
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reproduction in any medium, provided the oropen and laparoscopic procedures, but recent National
Comprehensive Cancer Network (NCCN) guidelines have
not yet described definite indications for these options [4].
Currently, laparoscopic wedge resection is a good surgical
option for gastric GIST and is an alternative to conven-
tional open surgery. However, there has been controversy
regarding tumor size in laparoscopic surgery for gastric
GISTs [5]. Recent reports show that laparoscopic or
laparoscopic-assisted resection may be used for small
gastric GISTs [6]. However, no report on the long-term
safety and efficacy of this surgery for large-sized gastric
GISTs has been published to date, even though some
publications showed its short-term feasibility for large
gastric GISTs.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ating the clinicopathological characteristics, postopera-
tive outcomes, patient survival, and tumor recurrence of
gastric GISTs after surgical treatment. Moreover, we
tried to confirm the safety and efficacy of laparoscopic
surgery for gastric GISTs larger than 5 cm in size.
Methods
Patients’ evaluation and work up
We reviewed the medical records of 104 patients with
gastric GISTs who underwent curative resection in
Dong-A University College of Medicine between July
1998 and January 2011. Patients with unresectable
metastasis or concurrent cancer other than gastric GIST
were excluded. We made the diagnosis of gastric GIST
by final pathology among the patients with gastric sub-
mucosal tumors which were found preoperatively by
esophagogastroduodenoscopy (EGDS), abdominal com-
puted tomography (CT), and endoscopic ultrasonog-
raphy (EUS).
According to risk classification suggested by Miettinen
et al., the gastric GISTs were divided into eight groups
based on maximum tumor diameter and mitotic activity
per 50 high-power fields (HPFs), as previously detailed
(Table 1) [7]. Patient characteristics, measured periopera-
tive parameters that included operation method and type
of resection, operative times, length of hospitalization,
complication, tumor recurrence, median follow-up periods,
and patient survival were evaluated. Also, we compared
the clinicopathologic characteristics and postoperative
outcomes of patients with large tumors (5 to 10 cm)
between laparoscopic and open surgery.Table 1 Suggested guidelines for assessing the malignant
potential of gastric GISTs of different sizes and mitotic
activity
Benign
Group 1 (no larger than 2 cm, no more than 5 mitoses/50 HPF)
Probably benign (very low malignant potential)
Group 2 (> 2 cm and ≤ 5 cm, no more than 5 mitoses/50 HPF)
Group 3a (> 5cm and ≤ 10 cm, no more than 5 mitoses/50 HPF)
Uncertain or low malignant potential
Group 4 (no larger than 2 cm, > 5 mitoses/50 HPF)
Low to moderate malignant potential
Group 3b (> 10 cm, no more than 5 mitoses/50 HPF)
Group 5 (> 2 cm and ≤ 5 cm, > 5 mitoses/50 HPF)
High malignant potential
Group 6a (> 5cm and ≤ 10 cm, > 5 mitoses/50 HPF)
Group 6b (> 10 cm, > 5 mitoses/50 HPF)
From [7].
GIST gastrointestinal stromal tumor, HPF high power field.Follow up methods and treatment
On very low- and low-risk groups according to a previ-
ous classification [8], CT was checked every 6 months
during first the 2-year period, and then every year during
next 3-year period. Endoscopy was performed every year
for the first 5 years. For the intermediate and high-risk
groups, CT was checked every 3 months for the first
2 years and then every 6 months for the next 3 years.
Endoscopy was performed every year for the first 5 years.
In cases of resectable tumor recurrence, we performed
additional surgery. In the other cases of unresectable
tumor recurrence, imatinib treatment was started at an
oral dose of 400 mg daily and was increased to 600 to
800 mg daily if the disease progressed.
Laparoscopic surgical procedure
After the induction of general anesthesia, the patient
was placed in the reverse Trendelenburg and supine pos-
ition. The surgeon stood on the patient’s right, with the
first assistant on the patient’s left and the camera oper-
ator on the surgeon’s right. Typically, an umbilical trocar
(10 mm) was inserted using the open method. A carbon
dioxide pneumoperitoneum was created using the um-
bilical port, and the pressure was maintained between 12
and 14 mmHg. A rigid (30 degree) laparoscope was then
introduced through the umbilical port. Under laparo-
scopic guidance, an additional two (5-mm and 12-mm)
trocars were introduced, consisting of the right subcostal
and right mid-abdominal ports. Occasionally, we inserted
an additional 5-mm trocar at the left mid-abdominal area
(Figure 1).
After the gastric wall had been devascularized and
exposed using Harmonic ACE (Ethicon Endo-Surgery,
Cincinnati, OH, USA), wedge resection of the gastric
wall was performed using laparoscopic stapling devices
(Echelon Flex, Ethicon Endo-Surgery, Cincinnati, OH,
USA).
Resected specimens were placed into an endoscopic
retrieval bag and extracted via the umbilical wound. In
all cases, our pathologist reported a free margin of nor-
mal gastric wall on frozen section biopsy. One closed
suction drain was placed around the surgical site at the
end of the procedure and trocar wounds were closed.
Statistical analysis
Chi-square and independent t-tests were used to com-
pare the clinicopathological factors of patients between
the laparoscopy and open surgery group using GraphPad
InStatW (version 3.06, GraphPad Software, Inc., La Jolla,
CA, USA). Statistical significance was assumed for
P-values < 0.05. Survival curves were calculated by the
Kaplan-Meier method. The log-rank test was used to
analyze survival differences and SPSS version 18.0 (SPSS,
Chicago, Ill, USA) was used for the analysis.
Figure 1 The locations, size and site of the trocar. Routinely,
three ports (5-mm, 11-mm, and 12-mm) were used during
laparoscopic surgery. Occasionally, if a further site was needed, a
5mm trocar was introduced into the left mid-abdominal area.
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Yearly operative trends for gastric GISTs
Figure 2 shows the operative methods (laparoscopic and
open) of the patients who underwent curative resections
in our institute during the period between 1998 and
2010. The numbers of laparoscopic cases has increased
annually.Figure 2 Yearly operative trends for primary gastric gastrointestinal s
increased annually since 2007.Patient characteristics
Table 2 shows a summary of clinical features of the
104 patients who underwent laparoscopic and open sur-
gery for gastric GISTs. There were 47 male and 57 female
patients, with a mean age of 59.8 ± SD 10.5 years. Forty
patients (38.5%) were diagnosed incidentally and were
asymptomatic. Among 64 (61.5%) symptomatic patients,
the most common symptom was pain. Sixty-one (58.7%),
24 (23.1%), and 19 (18.2%) of the 104 tumors were
located in the upper portion, middle portion, and lower
portion of the stomach, respectively. The patients were
subdivided into eight groups according to Miettinen’s
classification: 10 (9.6%) in group 1, 49 (47.1%) in group 2,
15 (14.4%) in group 3a, 9 (8.7%) in the group 5, 14 (13.5%)
in group 6a, and 7 (6.7%) in group 6b. Laparoscopic and
wedge operation were more frequently performed. Sur-
gical margins were all observed to be free on histo-
pathologic studies. There was no tumor rupture during
surgery. Among 104 patients, there was one minor com-
plication in a laparoscopic wedge resection. One patient
who experienced delayed gastric emptying was treated
with conservative care. Recurrences were noted in five
patients during a median follow-up period of 49.3 (range
8.4 to 164.4) months.
Clinicopathologic characteristics and postoperative
outcomes of laparoscopic and open surgery for larger 5
to 10 cm tumors
To evaluate differences between laparoscopic and open
surgery for larger tumor (5 to 10 cm), we compared the
two groups. There were statistically significant differ-
ences in age, tumor size, tumor location, and duration of
hospital stay (Table 3).tromal tumor (GIST). The numbers of laparoscopic resections has
Table 2 Characteristics and surgical outcomes of 104
patients with gastric gastrointestinal stromal tumor
(GIST)
Characteristic or outcome Value
Age, years* 59.8 ± 10.5
Gender
Male/female, n (%) 47 (45.2)/57 (54.8)










Upper/Middle/Lower, n (%) 61 (58.7)/24 (23.0)/19 (18.3)
Tumor size, cm* 5.1 ± 3.3
Prognostic group†, n (%)
Group 1 10 (9.6)
Group 2 49 (47.1)
Group 3a 15 (14.4)
Group 3b 0 (0)
Group 4 0 (0)
Group 5 9 (8.7)
Group 6a 14 (13.5)
Group 6b 7 (6.7)
Operation, n (%)
Laparoscopy/open 80 (76.9)/24 (23.1)
Type of resection
Wedge resection 90 (86.5)
Partial gastrectomy 9 (8.7)
Total gastrectomy 5 (4.8)
Status of surgical margin, n (%)
Positive/negative 0 (0)/104 (100)
Tumor rupture during operation, n (%)
No/yes 104 (100)/0 (0)
Operation times (minutes)*
Laparoscopy 91.1 ± 57.0
Open 165.8 ± 75.6
Length of hospitalization (days)*
Laparoscopy 4.6 ± 2.3
Open 9.8 ± 4.1
Complication, n (%)
Yes/no 1 (1.0)/103 (99.0)
Table 2 Characteristics and surgical outcomes of 104
patients with gastric gastrointestinal stromal tumor
(GIST) (Continued)
Recurrence
Yes/no 5 (4.8)/99 (95.2)
Median follow-up period, months, mean
(range)
49.3 (8.4, 164.4)
*Values are mean and standard deviation; †based on the Miettinen
classification; n, number of patients.
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Table 4 shows the clinicopathologic characteristics for
recurrent cases after curative resection. Tumors recurred
in five patients. The recurrent cases belonged to group 5,
6a, and 6b according to Miettinen’s classification. Initial
operations for these patients were open surgery in four
patients and laparoscopic surgery in one patient. Tumors
recurred in the peritoneum (two patients), the remnants
of the stomach (one patient), the liver (one patient) and
the colon (one patient). Three patients underwent reo-
peration, and two were treated only with imatinib
mesylate. Among the patients with tumor recurrence,
two have survived to date.
Survival
The 5-year overall and disease-free survival rates of gas-
tric GISTs were 98.6% and 94.8%, respectively (Figure 3).
Comparison of cases of laparoscopic and open surgery
for large tumors (5 to 10 cm) showed that there were
no statistically significant differences in 5-year overall
and disease-free survival rates between the two groups
(P = 0.067 and 0.083, respectively) (Figure 4).
Discussion
Surgical resection with negative margins without lympha-
denectomy has been the treatment of choice of gastric
GISTs up to now [1]. Histologically, a 1 to 2 cm margin
has been thought to be necessary for adequate resection
[9,10]. However, more recently, DeMatteo et al. [11] said
that tumor size and negative microscopic surgical mar-
gins did not determine the survival. It is therefore
accepted that the surgical goal should be complete resec-
tion with gross negative margins only [3,11]. Given this,
wedge resection has been advocated by many investiga-
tors for the majority of gastric GISTs [3,10,11]. Currently,
gastric GISTs are viewed as a good indication for laparo-
scopic resection. Moreover, the development of laparo-
scopic stapling devices and surgical techniques has made
laparoscopic wedge resection an attractive alternative to
conventional open surgery [12]. In this study, laparo-
scopic surgery has been performed with an annually
increasing tendency, and wedge resection was more
commonly advocated. This shows that laparoscopic wedge
Table 3 Clinicopathologic characteristics and
postoperative outcomes of laparoscopic and open
surgery for larger 5 to 10cm tumors
Laparoscopy
(n = 24)
Open (n = 14) P-value










Tumor size, cm* 6.1 ± 1.3 7.2 ± 1.7 0.035










Group 3a 5 1
Group 4 11 4
Group 5 2 1
Group 6a 6 8
Operative times,
minutes*
119.8 ± 62.2 154.3 ± 53.5 0.092









62.6 (8.9, 164.4) 58.3 (18.8, 123.2) 0.180
*Values are mean and standard deviation; †based on the Miettinen
classification; n number of patients.
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GIST.
Recent reports from the National Comprehensive
Cancer Network (NCCN) GIST Task Force and the GIST
Consensus Conference under the auspices of The Euro-
pean Society for Medical Oncology (ESMO) state that
laparoscopic or laparoscopic-assisted resection may beused for small gastric GISTs (that is, those < 2 cm in
size) [6]. However, Ronellenfitsch et al. [13] stated that
the tumor size did not determine the feasibility of lap-
aroscopic wedge resection, and the location of the
gastric GISTs did not directly affect the indication for
laparoscopic wedge resection. Whereas Yang et al. [14]
reported on the performance of laparoscopic wedge
resection for tumors less than 6 cm in diameter,
Ronellenfitsch et al. [13] and Huguet et al. [15] reported
its feasibility for tumors bigger than 10 cm in diameter.
The Japanese clinical practice guidelines for GIST suggest
that laparoscopic resection of gastric GISTs smaller than
5 cm appears safe when performed by a skillful surgeon
who is thoroughly familiar with the neoplastic character-
istics of gastric GISTs [16]. Before 2005, in our institute
we performed open surgery for tumors bigger than 5 cm
and for those located at the cardia. As our experience
has increased, we have been performing laparoscopic
surgery on tumors smaller than 10 cm regardless of their
location.
We classified the 38 patients who had large tumors
(5 to 10 cm) into those who received laparoscopic versus
open surgery. Although there were statistically significant
differences in age, tumor size, and tumor location, we
thought that these variables were not considered to be
factors that were comparable between laparoscopic and
open surgery. From the point of view of the merit of
laparoscopic surgery, the length of hospitalization was
statistically shorter in laparoscopic surgery than in open
surgery. Moreover, the operation time was shorter in
laparoscopic surgery, although there was no statistical
difference. In terms of survival rates, there were no statis-
tical differences in overall and disease-free survival rates,
although the survival graphs appeared to be different.
In the case of gastric GISTs bigger than 10 cm, sur-
geons were concerned about the operative methods of
laparoscopic versus open surgery. The merits of laparo-
scopic surgery included lesser degree of pain, smaller
wound size, shorter hospital stay, and earlier recovery.
However, in order to safely retrieve a mass bigger than
10 cm, a larger wound incision was needed, as in open
surgery. Moreover, laparoscopic surgical techniques
became more difficult in cases with bigger gastric GISTs,
and there was a possibility that tumor cells would spread
due to the rupture of the capsules. Therefore, with bigger
tumors, special attention should be paid to the preven-
tion of capsular rupture. It should also be emphasized
that careful laparoscopic evaluation of the tumor size,
and its characteristics in terms of the possibility of capsu-
lar rupture during further manipulations, should be per-
formed, giving timely conversion to the open method
whenever necessary. In our series, for the prevention of
tumor spread during laparoscopic surgery, we tried to
grasp the stomach and normal tissues around the tumor.
Table 4 Clinicopathologic characteristics of recurrent cases after curative resection




Type of operation Interval of
operation
(months)
Site of recurrence Treatment of
recurrence
Survival
1 F 65 5.0 Group 5 Open 51.8 Peritoneum Gleevec, reoperation Dead
2 M 37 9.0 Group 6a Open 59.7 Liver Reoperation Alive
3 F 64 21.0 Group 6b Open 5.1 Colon Gleevec Dead
4 F 63 9.0 Group 6a Laparoscopy 30.1 Stomach Reoperation Alive
5 F 81 7.6 Group 6a Open 14.7 Peritoneum Gleevec Dead
N patient number, F female, M male; †Based on the Miettinen classification.
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bigger than 10 cm, three of whom underwent laparo-
scopic surgery, while four underwent open surgery. In
addition, there were no capsular ruptures in the three
patients who had laparoscopic surgery.
The recurrence rate after surgery in reported series
ranges from 17 to 24% [17,18]. In recurrent gastric GISTs,
some reports demonstrated that a combination of sur-
gery and targeted therapy may reduce the development
of recurrence or decrease the risk of disease progression
[19,20]. Although most of our patients who underwent
surgical resection were at very low, or low malignant
potential (74/104, 71.2%), we had a lower recurrence
rate in our series compared to other reports [17,18].
We experienced five cases (5/104, 4.8%) of recurrence,
with a median follow-up time of 49.3 months (range,
8.4 to 164.4 months) after surgical resection for gastric
GISTs. Three patients underwent reoperation, and twoFigure 3 Survival characteristics of all 104 patients. The 5-year overall s
94.8%, respectively.were treated with imatinib mesylate. Unfortunately, none
of the patients responded to imatinib mesylate, and two
patients who underwent surgical management are cur-
rently living.
Although this was a retrospective research study of
laparoscopic and open surgery for gastric GIST, and
large tumors 5 to 10 cm in size, and although it was not
a case-matched study of laparoscopic and open surgery,
it provides a basic guideline to determine the size-related
indication for laparoscopic surgery for gastric GIST. A
prospective randomized controlled study of tumors
larger than 5 cm is necessary.
Conclusion
The clinical outcomes of gastric GISTs with very low
or low malignant potential were excellent. The group
of patients who had gastric GIST with high malignant
potential showed an increased recurrence rate and lessurvival rate (A) and disease-free survival rate (B) were 98.6% and
Figure 4 Comparison of the 5-year overall and disease-free survival rate between laparoscopic and open surgery for larger 5 to 10cm
tumors. The 5-year overall survival rates (A) and disease-free survival rates (B) were 100% and 92.9% (P = 0.067) and 95.0% and 66.3% (P = 0.083),
in the laparoscopic and open surgery groups respectively.
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In terms of the operative method, laparoscopic surgery
was an effective oncological treatment for gastric GIST.
Although this was a retrospective, research study in a
single institute, it is thought that laparoscopic surgery
would be a good alternative to open surgery for the treat-
ment of large gastric GIST bigger than 5 cm in size.
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